×
Back to Agenda
Drug Pricing in the United States: How and Why is it Different Than in the Rest of the World
Session Chair(s)
Christopher Marrone, PHARMD, RPH
Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO), Eli Lilly and Company, United States
Drug Pricing in the United States continues to be a hotly debated subject. As candidates head into the US 2020 election, the topic will only garner more attention. This session will review the differences in worldwide drug pricing regulations and practices. The future landscape of drug pricing in the United States will be discussed, with a review of drug pricing proposals.
Learning Objective : Compare US and non-US drug pricing regulations; Discuss the future landscape of US drug pricing;
Speaker(s)
Global Perspective: Benchmarking Prescription Drug Price and Access Around the World
Managing Partner, Citrus Health Group, United States
Pharmaceutical Pricing in the US Healthcare Market
Principal, JustSo Marketing, United States
Patient Affordability: Caught at the Intersection of Manufacturer and “System” Dynamics in Specialty Products
Senior Director, US Market Access, Apellis Pharmaceuticals, United States
Have an account?